Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01912534
Other study ID # VANISH
Secondary ID 5P50HL112349
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2014
Est. completion date July 2019

Study information

Verified date April 2020
Source HealthCore-NERI
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.


Description:

This is a multicenter, double-blind, placebo-controlled Phase II, randomized clinical trial to assess the safety and efficacy of valsartan in attenuating disease evolution in early HCM. Sarcomere mutation carriers with asymptomatic or mildly symptomatic overt disease (NYHA class I-II), and mutation carriers without left ventricular hypertrophy (LVH) will be studied.


Recruitment information / eligibility

Status Completed
Enrollment 211
Est. completion date July 2019
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender All
Age group 8 Years to 45 Years
Eligibility Inclusion Criteria: 1. All subjects must have a Pathogenic or Likely Pathogenic HCM Sarcomere Mutation a. The following categories of mutations are considered acceptable for subjects who have previously undergone clinical genetic testing. If results are ambiguous, they will be reviewed by the Clinical Coordinating Center to determine eligibility. - Laboratory for Molecular Medicine (Pathogenic, Likely Pathogenic) - Transgenomics/ PGXHealth (Class I) - GeneDx (Disease causing; Variant; likely disease-causing; Published, disease-causing mutation; Novel, likely disease-causing, mutation) - Correlagen (Associated; Probably Associated) Group 1 (Overt HCM Cohort) 1. LV wall thickness =12 mm and =25 mm or z score =3 and =18 as determined by rapid assessment by the echocardiographic core laboratory 2. NYHA functional class I or II; no perceived or only slight limitations in physical activities 3. No resting or provokable LV obstruction (peak gradient = 30 mmHg) on clinically-obtained Exercise Tolerance Test (ETT)-echo within the past 24 months or transthoracic echo with Valsalva maneuver within the past 12 months 4. Age 8-45 years 5. Able to attend follow-up appointments, complete all study assessments, and provide written informed consent Group 2 (Preclinical HCM Cohort (G+/LVH-)) 1. LV Wall Thickness <12 mm and z score <3 , as determined by rapid assessment by the echocardiographic core laboratory 2. Age 10-25 years 3. E' z score = -1.5 OR ECG abnormalities other than NSSTW changes (Q waves, T wave inversion, repolarization changes) OR LV wall thickness z-score 1.5-2.9 combined with LV thickness to dimension ratio =0.19 (as determined by rapid assessment by the echocardiographic core laboratory) 4. Able to attend follow-up appointments, complete all study assessments, and provide written informed consent Subject Exclusion Criteria 1. Contraindication to angiotensin receptor blocker (ARB) administration, including impaired renal function, hyperkalemia (serum K>5.0 mmol/L), prior history of angioedema 2. Medical conditions associated with increased collagen turnover that may confound interpretation of biomarkers of collagen synthesis (liver, pulmonary or renal fibrosis, inflammatory states, cancer, trauma or surgery within 6 months of enrollment) 3. Concomitant use of Spironolactone, Lithium, or Aliskiren, ARB or ACE-inhibitors. If these drugs are in active use but not necessary for medical care, they may be discontinued and baseline studies can be performed after a 2-week washout period. 4. Pregnant or breastfeeding females - Females of childbearing potential with no effective contraceptive method (including abstinence) 5. Uncontrolled systemic HTN [persistent SBP>160 and/or DBP>90 in adult or equivalent in children (e.g., SBP>99th or DBP>95th percentile for sex, age, and height centile based on the American Academy of Pediatrics normal values)] 6. Obstructive physiology, defined by resting, Valsalva-provoked or exercise-induced gradient >30mmHg within the past 24 months 7. Prior septal myectomy or alcohol septal ablation 8. Known, suspected, or symptomatic coronary artery disease or evidence of prior myocardial infarction based on symptoms or cardiac imaging 9. More than mild valvular heart disease or clinically significant congenital heart disease. Allowable conditions include bicuspid aortic valve without clinically significant stenosis or regurgitation; spontaneously closed ventricular septal defects; patent foramen ovale, small (= 2 mm) restrictive ventricular septal defects with normal ventricular size, and other minor defects that are considered allowable after [review and consensus by participating pediatric cardiologists, overall study PI and] adjudication by the echocardiographic core laboratory. 10. Left ventricular ejection fraction (LVEF) <55% 11. Concomitant medical conditions that would preclude performance of or confound interpretation of echocardiography, exercise testing, or CMR (e.g., renal insufficiency, lung disease, orthopedic/rheumatologic conditions, atrial fibrillation) 12. Secondary prevention implantable cardioverter-defibrillator device (ICD; primary prevention ICDs without a history of appropriate therapy, including shock or ATP, are allowable). 13. Prior treatment or hospitalization for symptomatic heart failure 14. Participation in a clinical trial (except observational studies) involving investigational medications within the previous 30 days.

Study Design


Intervention

Drug:
Valsartan
40, 80 and 160 mg tablets of Valsartan
Placebo
During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo

Locations

Country Name City State
Canada Toronto General Hospital Toronto Ontario
Canada Toronto Sick Kids Toronto Ontario
United States University of Michigan Ann Arbor Michigan
United States University of Colorado Aurora Colorado
United States Johns Hopkins University Baltimore Maryland
United States Brigham & Women's Hospital Boston Massachusetts
United States Children's Hospital Boston Boston Massachusetts
United States University of Chicago Chicago Illinois
United States Cinncinnati Children's Hospital Medical Center Cincinnati Ohio
United States Cleveland Clinic Foundation Cleveland Ohio
United States Vanderbilt University Nashville Tennessee
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States Washington University School Medicine Saint Louis Missouri
United States Stanford University Stanford California

Sponsors (2)

Lead Sponsor Collaborator
HealthCore-NERI National Heart, Lung, and Blood Institute (NHLBI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety of valsartan as assessed by incidence of adverse events Safety of valsartan as assessed by incidence of adverse events 2 years
Primary Composite z-score Composite z-score which is the average of 9 change-scores of: serum NTproBNP, serum high-sensitivity cardiac troponin, left ventricular (LV) mass, left atrial (LA) volume, LV end diastolic volume, LV end systolic volume, maximal LV wall thickness, echo E' velocity, echo S' velocity 2 years
Secondary z-score serum NTproBNP Z-score for the 2 year change for serum NTproBNP 2 years
Secondary z-score high sensitivity cardiac troponin Z-score for the 2 year change for high-sensitivity cardiac troponin 2 years
Secondary z-score LV mass Z-score for the 2 year change in LV Mass 2 years
Secondary z-score LA volume Z-score for the 2 year change in LA Volume 2 years
Secondary z-score LV end diastolic volume Z-score for the 2 year change in LV end diastolic volume 2 years
Secondary z-score LV end systolic volume Z-score for the 2 year change in LV end systolic volume 2 years
Secondary z-score maximal LV wall thickness Z-score for the 2 year change in Maximal LV wall thickness 2 years
Secondary z-score echo E' velocity Z-score for the 2 year change in echo E' velocity 2 years
Secondary z-score echo S' velocity Z-score for the 2 year change in echo S' velocity 2 years
Secondary Binary indicator of success or failure Success defined as an improvement at 2 years in any of the following: serum NTproBNP, serum high-sensitivity troponin, LV Mass, LA Volume, LV end diastolic volume, LV end systolic volume, Maximal LV wall thickness, echo E' velocity, or echo S' velocity 2 years
See also
  Status Clinical Trial Phase
Terminated NCT03249272 - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Phase 4
Recruiting NCT03846297 - Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
Completed NCT02806479 - Hypertrophic Cardiomyopathy Pilot Study
Active, not recruiting NCT01225978 - Refining Information Technology Support for Genetics in Medicine N/A
Completed NCT00001632 - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease N/A
Completed NCT00001534 - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease N/A
Enrolling by invitation NCT04050579 - OPIE in the Thin Interventricular Septum N/A
Completed NCT03537183 - Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? N/A
Completed NCT02590809 - Hypertrophic Cardiomyopathy Symptom Release by BX1514M Phase 2
Completed NCT00001396 - Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop... Phase 1
Active, not recruiting NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Phase 2/Phase 3
Completed NCT05135871 - Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects Phase 1
Completed NCT04129905 - Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies N/A
Recruiting NCT03061994 - Metabolomic Study of All-age Cardiomyopathy N/A
Completed NCT02234336 - Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Not yet recruiting NCT03706001 - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression N/A
Recruiting NCT06169358 - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Not yet recruiting NCT04090437 - HCM-AF Ablation With ACUTUS N/A
Completed NCT04402268 - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy